Knox v. Lederle Laboratories

4 F.3d 875
CourtCourt of Appeals for the Tenth Circuit
DecidedSeptember 8, 1993
DocketNo. 92-1341
StatusPublished
Cited by16 cases

This text of 4 F.3d 875 (Knox v. Lederle Laboratories) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Knox v. Lederle Laboratories, 4 F.3d 875 (10th Cir. 1993).

Opinion

McKAY, Chief Judge.

Appellant Wyeth Laboratories brings this interlocutory appeal pursuant to 28 U.S.C. § 1292(b) (1988) from the denial of its motion for summary judgment on grounds of claim preclusion.1 We affirm.

I

In 1986, Plaintiffs filed in Colorado state district court a product liability action against Wyeth, Lederle Laboratories, and Connaught Laboratories. We will refer to this earlier case as “Knox I.” Plaintiffs claimed that a vaccine manufactured by one of the defendants in Knox I caused severe injuries to the minor Plaintiff, Kenneth Knox.

After discovery, Wyeth moved for summary judgment based on an affidavit from a pharmacist that, according to the pharmacist’s records, Wyeth could not have manufactured the vaccine administered to Kenneth. The district court granted Wyeth’s motion and subsequently granted Plaintiffs’ motion for partial summary judgment against Lederle, relying on the same affidavit. Judgment was not actually entered on the motion, however.

After these summary judgment motions were decided, Wyeth ceased to participate in the case. It did not receive further pleadings or motions. On the other hand, neither did Wyeth seek a final judgment under Colo. R.Civ.P. 54(b).

In December of 1989, Plaintiffs decided to pursue a claim under the National Vaccine Injury Compensation Program (NVICP), 42 U.S.C. § 300aa-10 to -34 (1988), prior to continuing their suit. They invoked their right under 42 U.S.C. § 300aa-ll(a)(5)(A) (1988) to dismiss Knox I without prejudice and brought a claim under the NVICP. Wyeth received no notice of this dismissal and is not listed in the caption of the order dismissing the ease without prejudice.

The United States Court of Claims denied Plaintiffs any compensation. Knox v. Secretary of the Dep’t of Health & Human Servs., No. 90-33Y, 1991 WL 33242, 1991 U.S.Cl.Ct. Lexis 75 (Cl.Ct. Feb. 22, 1991). Pursuant to 42 U.S.C. § 300aa-21 (1988), Plaintiffs then elected to reject the resolution under the NVICP and file a new suit in Colorado state court. This present action (“Knox II ”) was removed to federal court on the basis of diversity of citizenship.

Initially, Plaintiffs only sued Defendant Lederle. When they sought to reimpose summary judgment on Lederle as the manufacturer of the vaccine that injured Kenneth Knox, Lederle produced a new affidavit from the same pharmacist, stating that newly discovered records forced him to recant his prior affidavit. The district court denied Plaintiffs’ motion for summary judgment.

Plaintiffs then rejoined Wyeth, which immediately filed a motion for summary judgment on res judicata grounds. The district court denied the motion, but granted Wyeth [878]*878leave to file an interlocutory appeal under 28 U.S.C. § 1292(b). We accepted the appeal.

II

We review the trial court’s action on a motion for summary judgment de novo. Clark v. Haas Group, Inc., 953 F.2d 1235, 1237 (10th Cir.), cert. denied, — U.S. -, 113 S.Ct. 98,121 L.Ed.2d 58 (1992). Because this case concerns a judgment of the Colorado state courts, we look to Colorado law. 28 U.S.C. § 1738 (1988).

The initial matter to be determined is the final status of Plaintiffs’ claim against Wyeth in Knox I. Wyeth claims that its summary judgment in Knox I became final with the dismissal of the other parties without prejudice in an order to which it was not a party. We conclude that Wyeth was a party to the order that dismissed Knox I without prejudice.

A

Rule 54(b) of the Colorado Rules of Civil Procedure, which is identical to the federal rule, states:

When more than one claim for relief is presented in an action, whether as a claim, counter-claim, cross-claim or third-party claim, or when multiple parties are involved, the court may direct the entry of a final judgment as to one or more but fewer than all of the claim or parties only upon an express determination that there is no just reason for delay and upon an express direction for the entry of judgment. In the absence of such determination and direction, any order or other form of decision, however designated, which adjudicates fewer than all the claims or the rights and liabilities of fewer than all the parties shall not terminate the action as to any of the claims, or parties and the order or other form of decision is subject to revision at any time before the entry of judgment adjudicating all the claims and the rights and liabilities of all the parties.

Colo.R.Civ.P. 54(b) (emphasis added). Wyeth never requested the district court to issue a final judgment as to it. Therefore, under the plain language of Rule 54(b), Wyeth remained a party to the action when Plaintiffs sought to dismiss without prejudice.

B

Wyeth argues that even if it was still a party to the action, the dismissal without prejudice did not apply to Plaintiffs’ claims against it. It states that “[Pjlaintiffs assert that they unilaterally dismissed ‘their action,’ i.e., all of their claims in Knox I [,] ... without addressing the undisputed fact that it was only their claims against Lederle that were dismissed by stipulation before their pursuit of Vaccine Program remedies.” (Appellant’s Reply Br. at 2.) The texts of the relevant documents do not support Wyeth’s argument.

The dismissal without prejudice reads as follows:

UPON STIPULATION of the parties to this action and consideration of all issues it is hereby ORDERED that this ease be DISMISSED on this date, WITHOUT PREJUDICE and WITHOUT COSTS.
It is FURTHER ORDERED that this DISMISSAL constitutes a WITHDRAWAL of this Civil Action as contemplated by the National Childhood Vaccine Injury Compensation Act of 1986, 42 U.S.C. § 300aa-ll.

(Appellant’s App. at 30-31.) Title 42 U.S.C. § 300aa-ll(a)(5)(A) in turn states:

A plaintiff who on October 1, 1988 has pending a civil action for damages for a vaccine-related injury or death may, at any time within 2 years after October 1, 1988, or before judgment, whichever occurs first, elect to withdraw such action without prejudice and file a petition under [the NVICP].2

Id.

Neither the dismissal nor the statute refers to individual claims. Rather, the dis[879]*879missal refers to the dismissal of the “case,” while the statute refers to the withdrawal of the “action.” As Colo.R.Civ.P.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
4 F.3d 875, Counsel Stack Legal Research, https://law.counselstack.com/opinion/knox-v-lederle-laboratories-ca10-1993.